Dana-farber-cancer Institute Inc.

Leland Stanford Junior University

Children's Medical Center Corporation

Novartis Ag

Harvard College

The Brigham and Women's Hospital, Inc.

The University of Birmingham

Children's Hospital

Boston Children's Hospital

Children's Medical Center Corporation Dana-farber Cancer Institute

Children's Hospital Boston

Dale T Umetsu

Gordon James Freeman

Rosemarie Dekruyff

Maximiliano Vasquez

Walter A Blattler

Thomas Huber

Daniel Hicklin

Jennifer Marie Mataraza

Barbara Brannetti

Catherine Anne Sabatos-Peyton

Fangmin Xu

Tiancen Hu

Thomas Pietzonka

John A Taraszka

Alan S Harris

Rosemarie H DeKruyff

Yanping Xiao

Samuel Strober

Arlene Helen Sharpe

Jennifer L Jones

Everett Hurteau Meyer

Susan Knox

Loise M Francisco

Rosemarie H De Kruyff

Jennifer Jones McIntire

Vijay K Kuchroo

Petr Illarionov

Stephanie Jemielity

Sanhong Yu

Ya-Jen Chang

Hyeryun Choe

Daniel J Hicklin

Arlene H Sharpe

The present invention relates to compositions and methods for the modulation RGMb-Neogenin-BMP signaling.

Agents that modulate RGMb-neogenin-BMP signaling and methods of use thereof

The present invention relates to compositions and methods for the immunomodulation mediated by the interaction of PD-L2 and RGMb.

Agents that modulate immune cell activation and methods of use thereof

Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.

Method of detecting TIM-3 using antibody molecules to TIM-3

The invention provides methods, compositions, and kits featuring agents that inhibit viral entry mediated by T-cell Immunoglobulin and Mucin-domain containing proteins (TIM proteins) and other phosphatidylserine receptors.

Compositions and methods for inhibiting viral entry

Antibody molecules to TIM-3 and uses thereof

A genetic locus and corresponding family of proteins associated with regulation of immune function and cell survival are provided. These genes encode cell surface molecules with conserved IgV and mucin domains. The locus comprising the TIM family is genetically associated with immune dysfunction, including asthma. Furthermore, the TIM gene family is located within a region of human chromosome 5 that is commonly deleted in malignancies and myelodysplastic syndrome. Polymorphisms in the gene sequences are associated with the development of airway hyperreactivity and allergic inflammation, and T cell production of IL-4 and IL-13. The proteins include the human hepatitis A cellular receptor, hHAVcr-1.

Modulation of TIM receptor activity in combination with cytoreductive therapy

The inventors demonstrate that treatment of young, suckling mice with a glycolipid derived fromactivates NKT cells in a CD1d-restricted fashion, and is protective against AHR in a model of allergen-induced asthma. The inventors further found that this protective effect can be transferred by NKT cells exposed to the glycolipid, and is associated with the expansion of a suppressive double-negative NKT cells and Foxp3Tcells. The inventors also demonstrate herein that pre-treatment of adult mice with a glycolipid derived frompartially suppresses airway hyperreactivity and inhibits BAL inflammation in an ozone-exposure model. Accordingly, provided herein are compositions and methods for the treatment and prevention of inflammatory diseases, such as asthma or autoimmune diseases, in a subject in need thereof.

Methods for the treatment and prevention of inflammatory diseases

Molecules that interact with the NKT cell antigen receptor and its counterpart antigen presenting molecule, but which inhibit the NKT cell immune function, are administered to a patient. Conditions of particular interest include the treatment of systemic lupus erythematosus (SLE), cancer, atherosclerosis, and allergic disease. In some embodiment of the invention, the inhibitory agent is an anergizing glycolipid, for example &#x3b2;-galactosylceramide. Pharmaceutical formulations of such glycolipids are provided, and find use in the treatment of diseases involving undesirable NKT cell activation.

Methods for relieving asthma-associated airway hyperresponsiveness

A genetic locus and corresponding family of proteins associated with regulation of immune development, function, and cell survival are provided. The locus comprising the TIM family is genetically associated with immune dysfunction, including atopy, autoimmunity, inflammatory bowel disease, dysplasia, and susceptibility to blood-bourne infectious diseases. Polymorphisms in the human TIM-1 gene and exposure to Hepatitis A Virus (HAV) are shown to be associated with protection from the development of atopy.

T cell regulatory genes associated with immune disease

Methods for inhibition of NKT cells

Growing community of inventors

Newton, MA, United States of America

Dale T Umetsu